South Africa faces a growing burden of chronic diseases, including diabetes, hypertension, cancer, HIV/AIDS, and rheumatoid arthritis. As treatment regimens become more complex and long-term adherence becomes essential, access to safe, effective, and affordable medicines is increasingly critical. Generic and biosimilar medicines are vital tools in addressing these challenges, enabling the healthcare system to broaden treatment coverage while managing costs.
Chronic conditions typically require sustained pharmacological therapy, sometimes over a patient’s lifetime. In this context, generic medicines offer proven, cost-effective alternatives to originator drugs. Once a patent expires, generics can enter the market at significantly reduced prices, often 80%–90% less than the branded version, without compromising efficacy or safety. This has been especially impactful in the case of HIV and tuberculosis, where public sector procurement of generics has enabled mass treatment access through programmes such as the national antiretroviral rollout [1][2].
Biosimilars are playing an increasingly important role in the treatment of chronic, high-cost conditions such as certain cancers, autoimmune diseases, and diabetes. For example, biosimilar versions of monoclonal antibodies, insulin, and growth hormones are now being used to expand access to biologic therapies that were previously unaffordable to many patients. While biosimilars offer more modest price reductions (typically 15–30%), the savings generated still allow for reinvestment in expanded care and earlier initiation of biologic treatment where clinically appropriate [3][4].
Affordability is a key concern for both the public and private sectors. In the public system, where over 80% of the population receives healthcare, budget constraints can limit the availability of originator biologics and specialty drugs [5]. The use of generics and biosimilars helps stretch limited resources and improves treatment continuity, particularly in chronic disease management. In the private sector, medical schemes and out-of-pocket payers also benefit from access to lower-cost equivalents, especially in cases where co-payments or non-formulary pricing limits patient access to originator brands.
The clinical integration of generics is well established in South Africa’s treatment guidelines, including for conditions such as epilepsy, hypertension, and diabetes. Biosimilars, though newer to the local market, are increasingly being included in clinical protocols. SAHPRA’s evolving regulatory stance on interchangeability, combined with international clinical trial data, supports their safe substitution under medical supervision [6][7].
However, uptake of biosimilars in South Africa has been slower than in other upper-middle-income countries. Factors include prescriber caution, patient awareness gaps, and limited inclusion in hospital formularies. Targeted education and training initiatives, particularly for chronic care specialists, can help address concerns related to immunogenicity, switching protocols, and pharmacovigilance [8].
Real-world evidence from international settings has demonstrated that biosimilars maintain safety and efficacy comparable to originator biologics in chronic disease treatment. Countries with robust biosimilar policies, such as the UK, Norway, and India, have reported improved access and system savings without compromising clinical outcomes [9]. As more biosimilars enter the South African market, supported by local regulatory guidance and global experience, their role in chronic disease management is expected to expand significantly.
The use of generic and biosimilar medicines in chronic care is not only a financial imperative, it is a clinical necessity. These alternatives support treatment equity, ensure continuity of care, and make it possible for more patients to receive effective, long-term therapy. As chronic disease prevalence continues to rise, these medicines will be essential components of a sustainable and inclusive health system.
Summary of Key Points
- Generics offer significant cost savings and are central to chronic care delivery in South Africa.
- Biosimilars are expanding access to high-cost biologic therapies used in oncology, diabetes, and autoimmune diseases.
- Both medicine types support affordability, treatment continuity, and health system sustainability.
- Education and policy support are key to increasing biosimilar uptake in chronic disease protocols.
References
[1] WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection.
[2] National Department of Health. Antiretroviral Procurement and Access Reports. https://www.health.gov.za
[3] IQVIA Institute. Biosimilars in Emerging Markets: Opportunities for Sustainable Access (2023).
[4] SAHPRA. Guideline on Similar Biological Medicines (Biosimilars). https://www.sahpra.org.za
[5] World Health Organization. South Africa Health System Review (2021).
[6] SAHPRA. Guideline Update: Interchangeability of Biosimilars.
[7] European Medicines Agency (EMA). Biosimilar Medicines Overview.
[8] MedSafety Exchange. Barriers to Biosimilar Uptake in Sub-Saharan Africa.
[9] NHS England. Biosimilars: Best Practice Evidence Review. https://www.england.nhs.uk